Join Growin Stock Community!

Neumora therapeutics, inc. common stockNMRA.US Overview

US StockHealthcare
(No presentation for NMRA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NMRA AI Insights

NMRA Overall Performance

NMRA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NMRA Recent Performance

-8.60%

Neumora therapeutics, inc. common stock

0.05%

Avg of Sector

-0.31%

S&P500

NMRA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NMRA Key Information

NMRA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NMRA Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Price of NMRA

NMRA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NMRA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
4.49
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
4.49
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%

  • When is NMRA's latest earnings report released?

    The most recent financial report for Neumora therapeutics, inc. common stock (NMRA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NMRA's short-term business performance and financial health. For the latest updates on NMRA's earnings releases, visit this page regularly.

  • How much debt does NMRA have?

    As of the end of the reporting period, Neumora therapeutics, inc. common stock (NMRA) had total debt of 20.09M, with a debt ratio of 0.11. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NMRA have?

    At the end of the period, Neumora therapeutics, inc. common stock (NMRA) held Total Cash and Cash Equivalents of 129.07M, accounting for 0.73 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NMRA's EPS continuing to grow?

    According to the past four quarterly reports, Neumora therapeutics, inc. common stock (NMRA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.35. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NMRA?

    Neumora therapeutics, inc. common stock (NMRA)'s Free Cash Flow (FCF) for the period is -46.56M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 39.06% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NMRA?

    The latest valuation data shows Neumora therapeutics, inc. common stock (NMRA) has a Price-To-Earnings (PE) ratio of -1.82 and a Price/Earnings-To-Growth (PEG) ratio of -0.21. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.